Zivo Bioscience, Inc. Common Stock
ZIVO
ZIVO was delisted on the 24th of November, 2023.
12 hedge funds and large institutions have $1.61M invested in Zivo Bioscience, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
54% less capital invested
Capital invested by funds: $3.49M → $1.61M (-$1.88M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.92K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$111 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$22 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$412K |
| 2 |
BlackRock
New York
|
-$12.2K |
| 3 |
JP Morgan Chase
New York
|
-$167 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $1.04M | -$412K | -37,000 | -22% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $360K | +$111 | +10 | +0% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $170K | +$27K | +2,423 | +12% |
|
|
4
Wells Fargo
San Francisco,
California
| $14.7K | +$22 | +2 | +0.1% |
|
|
VCA
5
Verdence Capital Advisors
Hunt Valley,
Maryland
| $13K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $6.96K | +$9.92K | +892 | New |
|
|
BCWM
7
Bartlett & Co Wealth Management
Cincinnati,
Ohio
| $1.3K | – | – | – |
|
|
BC
8
Bartlett & Co
Cincinnati,
Ohio
| $1K | – | – | – |
|
9
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $818 | – | – | – |
|
|
BCM
10
Bourgeon Capital Management
Darien,
Connecticut
| $41 | – | – | – |
|
|
11
JP Morgan Chase
New York
| $12 | -$167 | -15 | -88% |
|
|
12
BlackRock
New York
| – | -$12.2K | -837 | Closed |
|
ZIVO Hedge Fund Activity: Q3 2023 in Review
12 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Zivo Bioscience, Inc. Common Stock (ZIVO) for Q3 2023, worth a combined $1.61M — down 54% from $3.49M a quarter earlier.
Fund positioning in ZIVO was balanced in Q3 2023: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $27K. The largest seller was Armistice Capital, cutting an estimated $412K.
- 12 institutional investors held Zivo Bioscience, Inc. Common Stock (ZIVO) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $1.61M of Zivo Bioscience, Inc. Common Stock stock for Q3 2023, down 54% quarter-over-quarter.
- 1 fund opened new Zivo Bioscience, Inc. Common Stock positions in Q3 2023 and 1 closed out, a net change of 0 holders.
- The largest Zivo Bioscience, Inc. Common Stock buyer in Q3 2023 was Vanguard Group, an estimated $27K added.
- The largest Zivo Bioscience, Inc. Common Stock seller in Q3 2023 was Armistice Capital, an estimated $412K sold.
Based on aggregated 13F filings for Q3 2023.